Jul 5, 2023 7:00 am EDT Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
Jun 15, 2023 7:00 am EDT Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
Jun 6, 2023 4:30 pm EDT Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Jun 2, 2023 8:30 am EDT Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
May 9, 2023 7:00 am EDT Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
May 1, 2023 7:00 am EDT Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting
Apr 27, 2023 2:55 pm EDT Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind
Apr 26, 2023 7:00 am EDT Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
Apr 21, 2023 7:00 am EDT Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board